Evidence map›Paper›PMID 41311304›Full record

Trial reportEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2025

Women with persistent atrial fibrillation need more than pulmonary vein isolation: personalised extra-pulmonary vein ablation strategy vs. pulmonary vein isolation alone in the TAILORED-AF trial.

Isabel Deisenhofer, Julien Seitz, Marie-Sophie Nguyen-Tu, Sabine Lotteau, Clément Bars, Jean-Paul Albenque, Sonia Busch, Edouard Gitenay, Stavros Mountantonakis, Antoine Roux and 20 more

2 registry-linked trialsAbstract readRandomized Controlled TrialComparative StudyMulticenter Study
In one paragraph

Trial report in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04702451 nacompletednot on this map

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

TypeinterventionalSponsorVolta MedicalRan2021 to 2023Enrolled377ConditionsAtrial FibrillationArmsDispersion ablation + PVI, VX1, PVI
NCT07621055 recruitingnot on this mapstarted 2026, after this paper: background citation

Real-World Experience of Volta Medical AI-software During AF Ablation Using Next-generation Mapping and Ablation Technologies

TypeobservationalSponsorVolta MedicalRan2026 to 2030Enrolled150ConditionsAtrial Fibrillation, Atrial Arrhythmia, Arrhythmias, CardiacArmsCardiac mapping
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Pulsed field ablation for pulmonary vein isolation with or without posterior wall ablation in patients with persistent atrial fibrillation: a multicenter study.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026
    Article
  2. Diversity, equity, and inclusion in arrhythmia care: a European Heart Rhythm Association survey.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  3. Artificial intelligence for patient selection in pulsed-field ablation: promise, pragmatism, and the need for standards.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Isabel DeisenhoferDepartment of Electrophysiology, Technical University of Munich (TUM), German Heart Centre Munich, Lazarettstr. 36, 80636 Munich, Germany.ORCID 0000-0001-5826-6846
Julien SeitzHôpital Saint Joseph, Marseille, France.ORCID 0000-0001-8499-7167
Marie-Sophie Nguyen-TuVolta Medical, Marseille, France.ORCID 0000-0001-8762-8834
Sabine LotteauVolta Medical, Marseille, France.ORCID 0000-0002-6087-0521
Clément BarsHôpital Saint Joseph, Marseille, France.
Jean-Paul AlbenqueDepartment of Cardiology-Heart Rhythm Management, Clinique Pasteur, Toulouse, France.ORCID 0000-0003-3308-6077
Sonia BuschDepartment of Electrophysiology, Herz-Zentrum Bodensee, Konstanz, Germany.ORCID 0000-0003-0123-7213
Edouard GitenayHôpital Saint Joseph, Marseille, France.ORCID 0000-0003-1472-0773
Stavros MountantonakisNorthwell Cardiovascular Institute, New Hyde Park, NY, USA.ORCID 0000-0002-5641-3029
Antoine RouxPôle Santé République, Clermont-Ferrand, France.
Jérôme HorvilleurHôpital Privé Jacques Cartier-Ramsay Santé-Institut Cardiovasculaire Paris Sud, Massy, France.ORCID 0009-0000-6102-4709
Babe BakouboulaRhena, Strasbourg, France.ORCID 0000-0003-0210-8368
Saumil OzaAscension St. Vincent's Riverside Hospital, Jacksonville, FL, USA.ORCID 0000-0002-6120-9479
Selim AbbeyHôpital Privé Le Confluent, Nantes, France.
Guillaume TheodoreClinique Saint George, Nice, France.
Antoine LepillierCentre Cardiologique du Nord, Saint-Denis, France.ORCID 0000-0001-9757-362X
Yves GuyomarHôpital Saint Philibert, Lomme, France.ORCID 0009-0002-6057-6768
Francis BessièreHopital Cardiologique Louis Pradel, Institut Cardiologique de Lyon, Hospices Civils de Lyon, Lyon, France.ORCID 0000-0002-3642-9795
Jaap Jan SmitIsala Klinieken, Zwolle, The Netherlands.ORCID 0000-0003-2435-8165
Anil RajendraGrandview Medical Center, Arrythmia institute, Birmingham, AL, USA.ORCID 0000-0001-7607-1479
Daniel H CooperWashington University, St. Louis, MO, USA.ORCID 0009-0001-6017-6855
Haroon RashidInova, Fairfax, VA, USA.
Tom De PotterCardiovascular Center, AZORG, Aalst, Belgium.ORCID 0000-0003-1424-114X
Christian De ChillouDépartement de Cardiologie, CHU de Nancy, Nancy, France.ORCID 0000-0002-9025-6821
Seth GoldbargNew York Presbyterian Queens Division of Cardiology, Flushing, NYC, USA.ORCID 0000-0001-9820-4287
Atul VermaMcGill University Health Centre, Montreal, QC, Canada.ORCID 0000-0002-1020-9727
Gustavo MoralesGrandview Medical Center, Arrythmia institute, Birmingham, AL, USA.ORCID 0000-0002-4032-3184
Paola MilpiedVolta Medical, Marseille, France.
John D HummelThe Ohio State University Wexner Medical Center, Columbus, OH, USA.ORCID 0000-0002-2629-2553
Jérôme KalifaVolta Medical, Inc., Providence, RI, USA.ORCID 0000-0003-4166-1158

Funding

Volta Medical
6 · The paper itself

Abstract

aimsThere is still conflicting evidence if women with persistent atrial fibrillation (AF) profit from a pulmonary vein isolation (PVI) plus strategy. We evaluated the efficacy of a spatio-temporal dispersion-targeted ablation strategy in women from the TAILORED-AF trial. METHODS AND

resultsIn TAILORED-AF, 370 patients were randomised to either a personalised, artificial intelligence (AI)-guided tailored ablation or to PVI-only. AF substrate mapping data and 12-month ablation outcomes were compared between women and men. Overall, 21% patients were female (70.4 ± 6.9 vs. 64.5 ± 8.5 years for men, P < 0.001). While spatio-temporal dispersion extent was similar between groups, left atrial low-voltage surface area (<0.2 mV) was significantly larger in women (P < 0.01). In women, the single-procedure freedom from AF (76% vs. 50%, log-rank P < 0.001) and any atrial arrhythmia (56% vs. 38%, log-rank P < 0.05) were significantly superior to PVI alone with a tailored procedure. In the PVI-only group, the single-procedure freedom from AF (50% vs. 70%, log-rank P < 0.001) and any atrial arrhythmia (38% vs. 61%, log-rank P < 0.001) were significantly lower in women. After a tailored ablation, no significant differences were observed between women and men regarding freedom from AF (76% vs. 91%, log-rank P = 0.07) or any atrial arrhythmia (56% vs. 62%, log-rank P = 0.69) free survival.

conclusionCompared to men, PVI-only in women with persistent AF leads to a significantly lower freedom from atrial arrhythmia. A personalised spatio-temporal dispersion-targeted ablation strategy led to a higher rate of freedom from any atrial arrhythmia than standard PVI after a single procedure in women and comparable outcomes between women and men. REGISTRATION IDENTIFICATION: clinicaltrials.gov NCT04702451.

Indexed as

Atrial FibrillationCatheter AblationPulmonary VeinsAction PotentialsAgedArtificial IntelligenceFemaleHeart RateHumansMaleMiddle AgedRecurrenceSex FactorsTime FactorsTreatment OutcomeArtificial intelligenceatrial fibrillationCatheter ablationWomen

Identifiers

PMID41311304
PMCPMC12661116

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.